Strategic Importance of Real-World Data

The CaboLife (NCT07314164) clinical trial, a prospective, non-interventional observational study, aims to collect real-world evidence (RWE) to evaluate the effectiveness and safety of cabozantinib (Cabometyx) in actual clinical practice. Unlike traditional randomized controlled trials (RCTs), the data collected from a diverse patient population in a real-world healthcare setting will provide strong evidence to support the drug's duration of treatment (DoT) and demonstrate its safety profile. Cabozantinib, a multi-targeted tyrosine kinase inhibitor (TKI), simultaneously inhibits receptors such as VEGFR 1/2/3, MET, and AXL. Therefore, analyzing the impact of the drug's toxicity profile on patient compliance is crucial for establishing future prescribing guidelines.

Real-World Study Design Centered on Clinical Practice

This study, conducted at multiple clinics in Germany and Austria, is designed to include approximately 150 patients with progressive or metastatic pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET). Patients who have received at least one prior systemic therapy, excluding somatostatin analogs (SSA), will participate. The study will comprehensively track imaging results from CT and MRI scans, as well as blood tests measuring chromogranin A levels, without any additional interventions. The primary endpoints will be the disease control rate (DCR) at six months and progression-free survival (PFS), to verify whether the significant tumor suppression effect observed in the controlled Phase 3 trial is replicated in routine clinical practice.

Strengthening Market Positioning in Europe After Regulatory Approval

The launch of this observational study follows the recent FDA approval of cabozantinib for neuroendocrine tumors in March 2025 and is part of Ipsen's strategic marketing plan to support the European Medicines Agency (EMA) review and pricing negotiations. Despite the excellent clinical benefits demonstrated in the Phase 3 CABINET trial (pNET PFS of 13.8 months vs. 4.4 months for placebo), RWE demonstrating cost-effectiveness is essential to convince European health authorities, which have strict requirements for drug reimbursement and coverage. Therefore, the data and quality of life data (EORTC QLQ-C30) collected in the CaboLife study will serve as strong clinical evidence to demonstrate the differentiated value of cabozantinib compared to competing drugs in the European market.

Diverse Competitive Landscape and Securing Market Dominance

The global neuroendocrine tumor treatment market is currently characterized by intense competition among Novartis' lutetium lutetate (Lutathera), Pfizer's sunitinib (Sutent), and traditional somatostatin analogs. Cabozantinib, the first systemic therapy applicable to a broad patient population regardless of the primary site or somatostatin receptor expression, has a strong competitive advantage. However, competition with existing standard treatments is inevitable. Through this study, Ipsen aims to explore the potential for early administration and combination therapy with cabozantinib, absorb market share from Novartis and Pfizer, and create synergy with its Somatuline Depot to establish a strong neuroendocrine tumor portfolio.

Expanding Patient Access and Driving Long-Term Revenue Growth

Patients with neuroendocrine tumors who have previously received systemic therapy and experienced disease progression have limited subsequent treatment options, resulting in a significant unmet need. If cabozantinib proves to be safe and effective in preserving quality of life in real-world clinical practice, it will provide patients with a reliable second-line treatment option, significantly expanding treatment access. This will, in turn, drive long-term revenue growth for Ipsen in Europe and Canada and maximize milestone payments and royalties from its licensing partner, Exelixis, making it an attractive investment for the biopharmaceutical sector.